|
|
Post by mango on May 14, 2018 12:13:24 GMT -5
|
|
|
|
Post by mnholdem on May 14, 2018 13:55:59 GMT -5
Good job, dude!
|
|
|
|
Post by digger on May 15, 2018 9:00:43 GMT -5
I notice he says his "dream is to have an FDA leader who personally lives with type 1." Why just type 1?
Also, do any of Mannkind employees have either type 1 or 2 diabetes? It might be more convincing if some or, for that matter, the majority of the sales people actually had the ailment they are trying to sell treatment for.
|
|
|
|
Post by liane on May 15, 2018 9:55:51 GMT -5
digger - Your constant slamming of every single positive comment on this board is wearing thin. Be forewarned!
|
|
|
|
Post by sayhey24 on May 15, 2018 19:10:02 GMT -5
I notice he says his "dream is to have an FDA leader who personally lives with type 1." Why just type 1? Also, do any of Mannkind employees have either type 1 or 2 diabetes? It might be more convincing if some or, for that matter, the majority of the sales people actually had the ailment they are trying to sell treatment for. What else would you like the FDA leader to have, heart disease, peripheral neuropathy, retinopathy? Isn't T1 bad enough for you? Awhile back Mike was wearing a G5 and taking afrezza. You can do the same if you like. You don't need to be T2 to take afrezza or wear a CGM. Why don't you give it a try and see if you can mimic the VDex whitepaper and then report back on your findings especially severe hypos. www.v-dex.com/downloads/vdex-whitepaper-120917.pdf |
|
|
|
Post by joeypotsandpans on May 16, 2018 2:15:16 GMT -5
digger - Your constant slamming of every single positive comment on this board is wearing thin. Be forewarned! I don't how see how asking about Dr. Kendall's focusing on type 1 in the interview qualifies as "slamming." Same for suggesting more diabetic salespeople -- that just seems to make more sense. I'm pretty sure the FDA wouldn't object to a salesperson documenting their own success using afrezza. FYI, a fair amount of them are...and believe wholeheartedly in the product they are selling. It flies in the face of those that question their (the sales force) commitment and longevity with the company. |
|
|
|
Post by digger on May 16, 2018 7:27:48 GMT -5
I don't how see how asking about Dr. Kendall's focusing on type 1 in the interview qualifies as "slamming." Same for suggesting more diabetic salespeople -- that just seems to make more sense. I'm pretty sure the FDA wouldn't object to a salesperson documenting their own success using afrezza. FYI, a fair amount of them are...and believe wholeheartedly in the product they are selling. It flies in the face of those that question their (the sales force) commitment and longevity with the company. If that's true, then Mannkind should boast about it. The more I think about it, the more appealing I find the idea of diabetics selling to diabetics. Mannkind going out of its way to find diabetic sales reps and management candidates would make for a worthy promotion that could also boost the drug's presence in the diabetic community. |
|
|
|
Post by joeypotsandpans on May 16, 2018 7:43:34 GMT -5
FYI, a fair amount of them are...and believe wholeheartedly in the product they are selling. It flies in the face of those that question their (the sales force) commitment and longevity with the company. If that's true, then Mannkind should boast about it. The more I think about it, the more appealing I find the idea of diabetics selling to diabetics. Mannkind going out of its way to find diabetic sales reps and management candidates would make for a worthy promotion that could also boost the drug's presence in the diabetic community. Actually the CCO did point that out last night, for the amount of time and as interested and as fascinated as you appear to be in this company and it's story I fully would have expected you there or at the very least at the meeting this am. As one of your "friends" likes to always finish his articles with "stay tuned"!!!  |
|
|
|
Post by dreamboatcruise on May 16, 2018 12:04:33 GMT -5
FYI, a fair amount of them are...and believe wholeheartedly in the product they are selling. It flies in the face of those that question their (the sales force) commitment and longevity with the company. If that's true, then Mannkind should boast about it. The more I think about it, the more appealing I find the idea of diabetics selling to diabetics. Mannkind going out of its way to find diabetic sales reps and management candidates would make for a worthy promotion that could also boost the drug's presence in the diabetic community. Granted there may be some doctors that have diabetes, but pharma reps don't actually sell to the patients. Actually they are less sales reps than marketing reps. |
|
|
|
Post by kc on May 16, 2018 20:39:09 GMT -5
If that's true, then Mannkind should boast about it. The more I think about it, the more appealing I find the idea of diabetics selling to diabetics. Mannkind going out of its way to find diabetic sales reps and management candidates would make for a worthy promotion that could also boost the drug's presence in the diabetic community. Actually the CCO did point that out last night, for the amount of time and as interested and as fascinated as you appear to be in this company and it's story I fully would have expected you there or at the very least at the meeting this am. As one of your "friends" likes to always finish his articles with "stay tuned"!!! STAY TUNED! Shortly we will learn more. |
|
|
|
Post by mango on May 21, 2018 18:40:22 GMT -5
We should all have a sense of urgency, not because it’s about the company but because Afrezza is a tool that’s of immense value for people. If we’re not going to help people and make it available, we’re not fulfilling our personal and moral obligation to the Diabetes Community.
—Dr. David Kendall, March 1, 2018
|
|
